MLS Bio Appoints Adrian Hondros to the Board

Mr. Hondros brings nearly four decades of leadership experience across the financial services, construction, and healthcare sectors. He has held senior executive roles with NAB and CBA and served as Chief Executive Officer of St Andrew’s Australia and Porter Davis Homes. Most recently, he has been the Founder and Managing Director of Hondros Consulting, advising boards and CEOs on leadership, governance, and strategic growth.

As a shareholder and early investor in MLS Bio, Mr. Hondros has been an active supporter of the company’s mission to develop transformative therapies in oncology and infectious disease. His appointment to the Board reflects MLS Bio’s commitment to strengthening its governance and strategic capability during a pivotal stage of growth.

“Adrian has already contributed significantly to the direction of the company as an investor and advisor. His appointment as a director formally recognises his commitment and expertise, and positions MLS Bio to continue building strong investor confidence as we advance towards clinical development,” said Professor Albert Frauman, Founding Director of MLS Bio.

Mr. Hondros commented:

“I am delighted to join the Board at this exciting time for MLS Bio. I believe the company’s innovative platform is well placed to deliver meaningful advances in cancer and antiviral treatment. I look forward to working alongside the Founding Director to build commercial capacity to support the company’s vision and long-term success.”

The Board welcomes Mr. Hondros and looks forward to his ongoing contribution to MLS Bio’s strategic growth and value creation for all shareholders.